Supernus Pharmaceuticals (SUPN) 10-Q2015 Q1 Quarterly report

Filed: 6 May 15, 12:00am

Content analysis

Positive
Negative
Uncertain
Constraining
Legalese
Litigous
Readability	8th grade Avg

New words: accrual, Additionally, addressing, adherence, adjunctive, Advisory, Afecta, affirmative, al, allocated, allocation, area, authority, autism, back, bipolar, bloodstream, breakthrough, Cadila, calendar, care, CEO, CFO, chart, children, claimed, committee, conference, confirmed, coverage, damaged, declared, defective, deliver, department, directly, dispensing, distributor, efficient, eligibility, enable, enacted, examination, expert, fact, fleet, freight, gap, greater, hospitalization, inpatient, input, insert, institutional, insurance, intent, intermediary, January, Judge, knowledge, lab, largest, lead, LLC, longer, low, Magistrate, mandated, manner, Mannion, maximum, Medicaid, Medicare, minimum, monitoring, NDA, negotiated, NOL, noninfringement, norm, owe, owed, owing, package, Par, partially, peak, Pediatric, pending, percentage, plasma, pocket, point, portfolio, prescribed, pretrial, private, profile, qualified, quality, ranging, Rebate, redemption, registered, regulatory, request, resale, response, reverse, routine, Rule, Rune, sector, seizure, semi, separate, service, shelf, shipped, shortly, significantly, single, skipping, slower, smoother, spending, stage, statement, statutory, stockholder, suffer, suit, sustained, targeting, tenant, therapy, tolerability, tolerate, trend, Trileptal, trough, turn, TWi, typically, ultimate, uncertain, underlying, unpaid, unsuccessful, vary, view, viloxazine, voted, warehouse, Wholesale, wholesaler, worldwide

Removed: Abbreviated, Agent, aggregating, arisen, Bank, break, charge, commence, commitment, defense, demonstrating, description, develop, differentiated, error, experiencing, feedback, fifteen, Florida, hiring, important, investigator, line, National, Orenitram, organization, professional, relating, repayment, shown, simulation, treprostinil, Trustee, undergo

Search this filing

Filing tables

Export all tables to Excel

Filing exhibits

Related press release

SUPN similar filings

Filing view

Default size S M L
Default font Times Arial

External links

Share this filing

EXHIBIT 32.2

SUPERNUS PHARMACEUTICALS, INC.

CERTIFICATION PURSUANT TO

18 U.S.C. sec. 1350,

AS ADOPTED PURSUANT TO

SECTION 906 OF THE SARBANES-OXLEY ACT OF 2002

In connection with the Quarterly Report of Supernus Pharmaceuticals, Inc. (the “Company”) on Form 10-Q for the period ended March 31, 2015 as filed with the Securities and Exchange Commission on the date hereof (the “Report”), I, Gregory S. Patrick, Vice President and Chief Financial Officer of the Company, certify, pursuant to 18 U.S.C. sec. 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002, that:

(1) The Report fully complies with the requirements of section 13(a) or 15(d) of the Securities Exchange Act of 1934; and

(2) The information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of the Company.

Date: May 6, 2015	By:	/s/ Gregory S. Patrick

		Gregory S. Patrick
		Vice President and Chief Financial Officer

We use cookies on this site to provide a more responsive and personalized service. Continuing to browse, clicking I Agree, or closing this banner indicates agreement. See our Cookie Policy for more information.